share_log

Chardan Capital Maintains Buy on Orchestra BioMed Hldgs, Maintains $20 Price Target

Chardan Capital Maintains Buy on Orchestra BioMed Hldgs, Maintains $20 Price Target

查丹资本维持对Orchestra BioMed Hldgs的买入,维持20美元的目标股价
Moomoo 24/7 ·  03/28 08:49

Chardan Capital analyst Keay Nakae maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and maintains $20 price target.

Chardan Capital分析师Keay Nakae维持Orchestra BioMed Hldgs(纳斯达克股票代码:OBIO)的买入并维持20美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发